Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Share-based Compensation (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Share-based Compensation for 9 consecutive years, with $6.9 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation fell 27.85% year-over-year to $6.9 million; the TTM value through Mar 2026 reached $36.8 million, down 4.21%, while the annual FY2025 figure was $39.5 million, 3.63% up from the prior year.
  • Share-based Compensation hit $6.9 million in Q1 2026 for Bicycle Therapeutics, down from $11.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $11.7 million in Q4 2025 and bottomed at $5.4 million in Q3 2022.
  • Average Share-based Compensation over 5 years is $8.5 million, with a median of $9.0 million recorded in 2023.
  • Year-over-year, Share-based Compensation surged 166.89% in 2022 and then decreased 27.85% in 2026.
  • Bicycle Therapeutics' Share-based Compensation stood at $5.5 million in 2022, then soared by 41.01% to $7.8 million in 2023, then soared by 32.27% to $10.3 million in 2024, then increased by 12.77% to $11.7 million in 2025, then crashed by 40.53% to $6.9 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $6.9 million, $11.7 million, and $8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.